DiscoverRx for Biotech
Rx for Biotech
Claim Ownership

Rx for Biotech

Author: Podcast Host Christopher Leidli

Subscribed: 22Played: 220
Share

Description

"Rx for Biotech" is a healthcare education podcast dedicated to helping patients, caregivers, and healthcare professionals understand the rapidly evolving world of advanced therapies - and how patients can access them. From cell therapies and gene therapies to radiopharmaceuticals, immunotherapies, and next-generation treatments for cancer and autoimmune disease, this channel bridges the gap between breakthrough science and real-world patient care.

Hosted by Christopher Leidli, CEO of Genoplex, Inc., and longtime host of the Rx for Biotech podcast, each episode features conversations with:
• Biotech and pharmaceutical CEOs
• Physician leaders and researchers
• AI and tech leaders building tools to improve healthcare access
• Innovators building the next generation of personalized therapies

About Therapy4me.ai
Therapy4me.ai is a consumer education and care-navigation platform designed to help patients find and connect with specialists at treatment centers offering personalized medicines and advanced therapies.

Learn more: https://www.therapy4me.ai
To learn more about Genoplex, please visit https://www.genoplex.ai
Media and Speaking Inquiries: https://christopherleidli.com
97 Episodes
Reverse
What if we could deliver powerful radiation directly to cancer cells while limiting damage to surrounding healthy tissue? A new generation of cancer treatments called targeted alpha therapies is emerging as one of the most promising areas of precision oncology. By combining tumor-targeting molecules with highly energetic radioactive isotopes, scientists are developing therapies designed to attack cancer at the cellular level. In this episode of Rx for Biotech, host Christopher Leidli interviews Frédéric Desdouits, CEO of Orano Med, to explore the science behind lead-212 (Pb-212) targeted alpha therapy, the future of radioligand therapy, and what these emerging treatments could mean for patients with difficult-to-treat cancers. How does targeted alpha therapy work? Traditional radiation therapy uses external beams to target tumors. Targeted alpha therapy takes a different approach. Orano Med is developing investigational radiopharmaceuticals that combine three components: • A targeting molecule, such as a peptide or antibody, designed to recognize specific features on cancer cells. • Lead-212, a radioactive isotope that produces alpha-emitting particles through its decay chain. • A chemical linker, called a chelator, that holds the radioactive isotope and targeting molecule together. Once delivered to the tumor, the radioactive payload can release highly energetic alpha particles capable of causing severe DNA damage to nearby cells. Unlike radiation that travels over longer distances, alpha particles travel only a few cell layers through tissue. This short range creates the potential to concentrate radiation damage near targeted cancer cells while reducing exposure to neighboring healthy tissues. Developing the next generation of cancer treatments requires more than demonstrating powerful antitumor activity. Researchers must also establish an acceptable balance between efficacy, safety, and quality of life. Cancer treatment is undergoing a fundamental transformation. Instead of relying exclusively on treatments that affect rapidly dividing cells throughout the body, researchers are increasingly developing therapies designed around the unique molecular characteristics of tumors. Targeted alpha therapy represents an important investigational approach within this broader movement toward precision oncology. For patients and caregivers, understanding these advances can help inform conversations with oncologists about molecular imaging, radioligand therapies, and clinical trial opportunities. For healthcare professionals, biotechnology leaders, and investors, the conversation offers insight into the scientific, manufacturing, and commercial challenges shaping this rapidly evolving field. Learn more Orano Med - Targeted Alpha Therapy: https://www.oranomed.com/en/targeted-alpha-therapy Orano Med - Clinical Pipeline: https://www.oranomed.com/en/pipeline About Rx for Biotech Rx for Biotech explores the scientific breakthroughs, technologies, and people transforming the future of healthcare. Hosted by Chris Leidli, Founder and CEO of Genoplex, the podcast features conversations with biotechnology executives, physicians, scientists, and healthcare innovators working to expand access to personalized medicine and advanced therapies. Medical disclaimer: This episode is provided for educational and informational purposes only. Investigational therapies discussed are not established treatments, and early clinical findings do not guarantee future approval or patient benefit. Consult your healthcare provider about appropriate treatment options and clinical trials.
AI is no longer just writing emails, summarizing documents, or answering questions. The rise of agentic AI is transforming how organizations make decisions, automate workflows, manage risk, and deliver services - especially in highly regulated industries such as healthcare, biotechnology, pharmaceuticals, and hospital systems. In this episode of Rx for Biotech, host Chris Leidli meets with Bennet Borden, lawyer, data scientist, and founder of Clarion AI, an AI-native legal and technology consultancy, to explore why this next wave of artificial intelligence could fundamentally reshape the future of professional services and healthcare. Bennet brings an unusual perspective to the AI revolution. His career spans intelligence analytics, leading global law firms, AI governance, enterprise technology, and the development of AI-powered systems. As AI moves from generating content to taking action, healthcare organizations face a new challenge: How do you safely deploy AI systems that make recommendations, perform tasks, and influence decisions affecting real people? Bennet explains why successful AI transformation requires that organizations rethink workflows, how to unlock proprietary data, develop specialized AI agents, and build governance directly into their systems. And perhaps most importantly, they must understand that AI transformation is as much about people as technology. In this episode, we discuss: • Generative AI vs. agentic AI: Why moving from generating content to performing tasks changes everything. • AI and the future of law: The analysis of 14,000 attorneys and why traditional professional services are facing disruption. • Agentic AI in healthcare: Opportunities for medical documentation, clinical decision support, diagnostic workflows, and patient services. • AI governance and compliance: How pharmaceutical companies and hospital systems can manage AI risk, safety, accountability, and regulatory uncertainty. • The AI black-box problem: Why measuring what AI systems actually do matters more than debating how they work internally. • Build vs. buy: Why general-purpose AI tools may deliver productivity improvements but not lasting competitive differentiation. • Enterprise data and AI agents: How organizations can leverage internal knowledge and expertise through specialized agentic workflows. • AI transformation and change management: Why Bennet describes transformation as 20% technology and 80% psychology. • Human expertise and AI augmentation: Why the goal should be Iron Man, not the Terminator. • AI vendor contracts: What healthcare and life sciences organizations should consider when evaluating accountability, indemnification, and risk allocation. • The future of AI in healthcare: Why the human relationship between patients and clinicians remains essential. Whether you are a biotechnology executive, pharmaceutical leader, clinician, hospital administrator, attorney, AI developer, or investor, this conversation offers a practical perspective on adopting artificial intelligence responsibly while remaining competitive. Connect with Bennet Borden at Clarion AI Partners Website: https://clarionailaw.com About "Rx for Biotech" Podcast Rx for Biotech explores how biotechnology, artificial intelligence, precision medicine, and advanced therapies are transforming healthcare. Hosted by Chris Leidli, Founder and CEO of Genoplex, the podcast features conversations with executives, physicians, scientists, and innovators building the future of medicine. Subscribe to Rx for Biotech for more conversations on agentic AI, biotechnology innovation, healthcare technology, personalized medicine, and patient access. This episode is intended for educational and informational purposes and does not constitute legal, regulatory, or medical advice.
What if your fatigue, anxiety, weight gain, poor sleep, low libido, or brain fog are not “just stress”? Too many women are told they are stressed, anxious, depressed, or “just getting older” when their symptoms may deserve a deeper look. In this episode of Rx for Biotech, host Chris Leidli sits down with Sharon Lemoine, ARNP, Owner of Gig Harbor Medical Center, to discuss women’s health, hormone therapy, menopause, functional medicine, concierge care, peptides, GLP-1s, and the growing demand for a more personalized model of healthcare. Sharon brings a rare perspective to this conversation. She spent 25 years in emergency medicine before building a faith-based functional medicine and concierge care practice in Gig Harbor, Washington. Her clinical journey was also shaped by her own health experiences, including Type 1 diabetes, surgical menopause, Graves’ disease, and thyroid cancer. That combination of provider experience and patient experience now informs how she cares for midlife women and men who feel unheard, rushed, or dismissed by conventional healthcare. A major theme of this episode is that many patients - especially women navigating perimenopause and menopause - are told their symptoms are simply stress, aging, anxiety, or depression. Sharon explains why symptoms such as fatigue, irritability, mood changes, weight gain, poor sleep, low libido, and loss of muscle may deserve a deeper evaluation, including hormones, thyroid function, metabolic health, nutrition, and lifestyle. This conversation is especially relevant for women in their 30s, 40s, 50s, and beyond who are navigating unexplained symptoms, hormone changes, menopause, weight gain, fatigue, anxiety, low libido, poor sleep, or frustration with rushed medical visits. It is also relevant for men interested in testosterone, metabolic health, energy, longevity, and performance as they age. Sharon’s central message is clear: patients should not discount their symptoms. If you feel unheard, rushed, or dismissed, it may be time to find a provider who will take the time to understand the full picture. Subscribe to "Rx for Biotech" channel for conversations with clinicians, founders, scientists, and healthcare leaders shaping the future of personalized medicine, advanced therapies, longevity, and patient-centered care. This episode is for educational purposes only and should not be interpreted as medical advice. Always speak with a qualified healthcare professional before starting, stopping, or changing any medical treatment. #WomensHealth #HormoneHealth #Menopause #Perimenopause #Testosterone #FunctionalMedicine #ConciergeMedicine #GLP1 #Peptides #Longevity #ThyroidHealth #MetabolicHealth #PatientAdvocacy #RxForBiotech
We all know that cancer is caused by the rapid growth of tumor cells - but the ability for cancer to hide from the immune system is also a big challenge that scientists face when designing new therapies. In this episode of Rx for Biotech, host Chris Leidli speaks with John Friend, MD, CEO of Kazia Therapeutics, about a new approach to some of the most difficult-to-treat cancers, including glioblastoma, pediatric brain tumors, brain metastases, and triple-negative breast cancer. Dr. Friend uses a powerful metaphor throughout the conversation: many tumors develop something like an “invisibility cloak.” They adapt, resist treatment, avoid immune detection, and become harder for standard therapies to eliminate. Kazia Therapeutics is working to change that. The conversation centers on paxalisib, Kazia’s investigational brain-penetrant therapy designed to inhibit both PI3K and mTOR, two important cancer growth and survival pathways. John explains the PI3K pathway using a simple analogy: in cancer, this pathway can act like an accelerator stuck in the “on” position. By targeting PI3K and mTOR together, paxalisib is designed not only to take the foot off the accelerator, but also to apply the brakes. A major focus of the episode is glioblastoma, one of the most aggressive and difficult-to-treat brain cancers. John explains why glioblastoma has been so challenging for drug development, including tumor complexity, resistance, and the difficulty of getting drugs across the blood-brain barrier. Paxalisib was specifically designed to cross the blood-brain barrier—an essential feature for any therapy being developed for brain tumors. John also discusses Kazia’s expanding work in triple-negative breast cancer, where the company is studying paxalisib as an add-on to standard-of-care treatment with pembrolizumab plus chemotherapy. The goal is not simply to kill tumor cells directly, but to potentially reprogram resistant cancer cells, reduce circulating tumor cells, and make tumors more vulnerable to existing therapies and immune attack. In this episode, we discuss: • Why glioblastoma remains one of the hardest cancers to treat • What makes the blood-brain barrier such a major challenge in brain cancer drug development • How paxalisib was designed to cross the blood-brain barrier • Why the PI3K/mTOR pathway matters in cancer growth and resistance • The “accelerator and brake” analogy for PI3K and mTOR inhibition • Why Kazia is studying paxalisib in glioblastoma, pediatric brain tumors, brain metastases, and breast cancer • What makes triple-negative breast cancer so difficult to treat • How tumors can evade treatment through an “invisibility cloak” • Why combination therapy is increasingly important in oncology • How paxalisib may help reprogram resistant cancer cells • Early signals from Kazia’s triple-negative breast cancer work • Kazia’s emerging pipeline, including cancer-specific PD-L1 protein degradation • Why future cancer therapy may depend on making tumors visible again • Upcoming clinical and corporate milestones for Kazia Therapeutics This conversation is especially relevant for patients, caregivers, clinicians, researchers, biotech investors, and anyone interested in the future of brain cancer treatment, glioblastoma research, triple-negative breast cancer, targeted oncology, immunotherapy resistance, and precision medicine. Subscribe to Rx for Biotech for conversations with biotech CEOs, physicians, scientists, and industry leaders developing the next generation of personalized medicines and advanced cancer therapies. This episode is for educational purposes only and should not be interpreted as medical advice. Investigational therapies discussed in this conversation have not necessarily been established as safe or effective by regulatory authorities.
Can precision oncology help identify cancer’s genetic weaknesses and turn them into therapeutic opportunities? In this episode of "Rx for Biotech", host Chris Leidli speaks with Oren Gilad, CEO of Aprea Therapeutics, about the rapidly evolving field of synthetic lethality, DNA damage response, and targeted cancer therapies designed to exploit vulnerabilities in cancer cells. Oren shares how his scientific journey began at the University of Pennsylvania, where early experiments studying ATR helped shape the foundation for Aprea’s current cancer drug development strategy. That work led to a central insight behind synthetic lethality: cancer cells with specific genetic mutations may become highly dependent on certain DNA repair and checkpoint pathways for survival. Aprea is developing a pipeline of precision oncology therapies focused on what Oren describes as multiple targets in one critical pathway, including WEE1, ATR, p53 reactivation, and DYRK1 inhibition. A major focus of the conversation is APR-1051, Aprea’s investigational oral WEE1 inhibitor, which is being studied in patients with cancers carrying specific genetic alterations. Oren explains how WEE1 functions as a checkpoint in cell division, why cancer cells can become especially dependent on this pathway, and how inhibiting WEE1 may selectively target tumor cells while aiming to preserve a wider therapeutic window. This episode is especially relevant for anyone interested in precision medicine, targeted cancer therapy, DNA repair, synthetic lethality, oncology clinical trials, cancer biomarkers, and the future of drug development. Subscribe to Rx for Biotech podcast for conversations with biotech CEOs, scientists, physicians, and industry leaders developing the next generation of personalized medicines. This podcast is for educational purposes only and should not be interpreted as medical advice. Investigational therapies discussed in this episode have not necessarily been established as safe or effective by regulatory authorities.
loading
Comments